CRNX, RUBY To Debut On Nasdaq, CLRB On Watch, PULM To Advance Pulmazole In Q4

Today's Daily Dose brings you news about IPOs of Crinetics Pharma and Rubius; secondary offerings of Cara, Oragenics and CytomX, and promising efficacy of Cellectar Biosciences' drug candidate CLR 131 observed in a single patient in a phase II trial.

from RTT - Biotech https://ift.tt/2NmRf06
via IFTTT